Palisade Bio Inc. (NASDAQ:PALI) saw a 5.26% jump in its stock price on Wednesday as investors eagerly awaited the results of its clinical trial for fibrostenotic Crohn’s disease treatment. The company plans to reveal the Phase 1b study results of PALI-2108 in the first quarter of 2026, with an IND submission in the first half of next year. The first phase of the trial consisted of 6 to 12 FSCD patients and assessed the efficacy of PALI-2108 over a 14-day treatment period.

Year-to-date, Palisade Bio Inc. (NASDAQ:PALI) shares have risen by an impressive 33.33%. The company is focused on developing once daily, oral PDE4 inhibitor prodrugs for patients with inflammatory and fibrotic diseases. While PALI shows potential as an investment, some believe that AI stocks offer greater returns with limited downside risk. For those interested in an inexpensive AI stock with potential benefits from Trump tariffs and onshoring, a free report is available.

The recent surge in Palisade Bio Inc. (NASDAQ:PALI) stock can also be attributed to institutional investors engaging in window-dressing activities. This practice involves adjusting portfolios before reporting periods by increasing holdings in well-performing stocks like PALI and reducing exposure to underperforming assets. This strategy aims to present a stronger portfolio to clients during quarterly and annual reports.

Read more at Yahoo Finance: Palisade Bio (PALI) Soars 5% Ahead of Clinical Trial Results